Osteoporosis

• Osteoclast activation and RANK/RANKL pathway dysfunction: Osteoclasts are multinucleated giant cells derived from hematopoietic precursor cells (monocyte/macrophage lineage) that resorb bone through secretion of hydrogen ions and proteolytic enzymes (cathepsin K, matrix metalloproteinases). Osteoclast differentiation and activation are regulated by the RANK/RANKL/OPG axis. Receptor activator of nuclear factor kappa-B ligand (RANKL) is produced by osteoblasts and T cells and binds to RANK on osteoclast precursors, promoting their differentiation and activation. Osteoprotegerin (OPG), produced by osteoblasts, acts as a soluble decoy receptor that competitively inhibits RANKL, thereby suppressing osteoclastogenesis. In osteoporosis, there is increased production of RANKL relative to OPG—driven by estrogen deficiency, inflammation, and systemic factors—tilting the balance toward enhanced bone resorption. The increased RANKL/OPG ratio is a fundamental pathologic mechanism in postmenopausal osteoporosis.

• Estrogen deficiency and immune dysregulation: Estrogen is a critical regulator of bone homeostasis that acts through estrogen receptors (ER-α and ER-β) on osteoblasts, osteocytes, and immune cells. The dramatic bone loss following menopause (1-3% annually for 5-10 years) results from abrupt withdrawal of estrogen's inhibitory effects on bone resorption. Estrogen normally suppresses production of pro-resorptive cytokines (TNF-α, IL-1, IL-6) by T cells and macrophages and directly inhibits osteoclast formation through downregulation of RANKL expression on osteoblasts and T cells. Estrogen deficiency leads to: (1) increased T cell activation and IL-17 production with downstream IL-6 and TNF-α generation; (2) enhanced osteoclast precursor recruitment and differentiation; (3) prolonged osteoclast lifespan; and (4) reduced osteoblast differentiation and function. This creates a pro-resorptive immune environment that dominates the early postmenopausal period.

• Osteoblast dysfunction and impaired bone formation: Osteoblasts originate from bone marrow mesenchymal stem cells and are responsible for synthesizing and mineralizing new bone matrix. In osteoporosis, osteoblast function is impaired through multiple mechanisms: (1) reduced osteoblast differentiation due to decreased Wnt/β-catenin signaling and increased sclerostin (a Wnt antagonist) from osteocytes; (2) diminished osteoblast lifespan through increased apoptosis driven by reactive oxygen species (ROS) and pro-inflammatory cytokines; (3) impaired osteoid mineralization due to abnormalities in phosphate and calcium homeostasis; and (4) reduced production of Type I collagen, the primary organic matrix component. The result is inadequate osteoblast-mediated bone formation that fails to match the increased resorptive activity of osteoclasts, creating a negative bone balance. Aging additionally impairs osteoblast function independent of hormonal factors through accumulation of senescent cells and mitochondrial dysfunction.

• Bone microarchitecture deterioration: Normal bone maintains structural integrity through a combination of trabecular (cancellous) and cortical (compact) bone. Trabecular bone, comprising 20% of total bone mass but constituting 80% of surface area, is metabolically active and highly responsive to systemic factors. In osteoporosis, preferential loss of trabecular bone occurs through: (1) thinning and perforation of trabeculae; (2) loss of horizontal trabeculae that provide cross-bracing; (3) conversion of plate-like trabeculae to rod-like structures with reduced load-bearing capacity; and (4) increased marrow space. These architectural changes reduce bone quality disproportionately to the loss of bone mass, explaining why some patients with modest reductions in BMD sustain fractures while others with lower BMD do not. Cortical bone thinning also occurs through increased endocortical resorption and decreased periosteal apposition, further compromising structural integrity.

• Calcium and phosphate homeostasis abnormalities: Chronic negative calcium balance contributes to osteoporosis development. Although serum calcium is tightly regulated by PTH and vitamin D, chronic inadequate calcium intake or vitamin D deficiency shifts bone to serve as the calcium reservoir. Vitamin D deficiency (serum 25-hydroxyvitamin D <20 ng/mL) leads to secondary hyperparathyroidism, which drives increased bone resorption to maintain serum calcium normalization. This creates a vicious cycle of increased PTH-mediated osteoclast activation and bone loss. Phosphate metabolism is similarly deranged in some osteoporotic states, with altered FGF23 signaling affecting both renal phosphate handling and vitamin D metabolism.

• Oxidative stress and molecular aging: Accumulation of reactive oxygen species (ROS) in bone microenvironment promotes osteoblast apoptosis and osteoclast activation while inhibiting osteoblast differentiation through impairment of Wnt/β-catenin signaling. ROS-induced endothelial dysfunction reduces blood flow to bone, impairing nutrient delivery. Oxidative stress also impairs Type I collagen cross-linking, reducing bone matrix quality even when matrix quantity remains relatively preserved. This mechanism explains why antioxidant activity of agents like estrogen is important and why aging inherently increases osteoporosis risk.

• Postmenopausal estrogen deficiency: This is the most common cause of osteoporosis in women, accounting for the majority of cases in women aged 50-75 years. The rapid bone loss phase occurs in the 5-10 years immediately following menopause, with bone loss rates of 1-3% annually at the hip and even higher at the spine. The mechanism involves the estrogen-responsive changes in immune regulation and osteoclast activation detailed above. Family history of early menopause or osteoporosis accelerates and amplifies this process through genetic predisposition to estrogen sensitivity.

• Age-related bone loss in men: While men do not experience the acute hormonal changes of menopause, testosterone and estrogen (produced peripherally from androgens via aromatase) both decline gradually with advancing age (approximately 0.5-1% annually after age 30). Men develop symptomatic osteoporosis later than women (typically >70 years) due to: (1) higher peak bone mass achieved in young adulthood; (2) slower rate of age-related bone loss; and (3) no equivalent of menopause-accelerated resorption. However, men with hypogonadism (whether from primary or secondary testicular failure, or from medications like androgen deprivation therapy) experience accelerated bone loss comparable to postmenopausal women.

• Glucocorticoid excess (endogenous or exogenous): Glucocorticoids cause osteoporosis through multiple mechanisms: (1) direct suppression of osteoblast differentiation and function through GR-mediated transcriptional changes; (2) increased osteoblast apoptosis; (3) enhanced osteoclast survival and activity; (4) impaired intestinal calcium absorption through reduced 1,25-dihydroxyvitamin D production; (5) increased urinary calcium excretion; and (6) suppression of testosterone and estrogen production. Chronic corticosteroid use (particularly doses ≥7.5 mg prednisone daily for >3 months) causes 1-3% annual bone loss, with the greatest loss occurring in the first 6-12 months of therapy. Patients receiving inhaled corticosteroids at high doses may also be at increased risk. Cushing's syndrome and primary adrenal insufficiency (treated with glucocorticoid replacement) both predispose to osteoporosis.

• Thyroid disease and excess thyroid hormone: Hyperthyroidism, whether from Graves' disease, toxic nodules, thyroiditis, or excess levothyroxine (iatrogenic), increases bone turnover with resorption exceeding formation. Thyroid hormone directly enhances osteoclast activation through RANKL upregulation and increases osteoblast expression of sclerostin. Excess thyroid hormone also increases adrenergic signaling on osteoblasts, promoting their apoptosis. The effect is dose-dependent, making patients on suppressive levothyroxine therapy (e.g., post-thyroidectomy for cancer) at particular risk. TSH suppression below the normal range is associated with bone loss regardless of whether hyperthyroidism is endogenous or iatrogenic.

• Hypogonadism in men and women: Beyond natural menopause, acquired hypogonadism from any cause (hypogonadotropic or hypergonadotropic hypogonadism) predisposes to osteoporosis. In women, early menopause (<45 years), prolonged amenorrhea from disordered eating or excessive exercise, or surgical oophorectomy accelerate osteoporosis. In men, androgen deprivation therapy (ADT) for prostate cancer causes 2-3% annual bone loss. Primary testicular failure (from hemochromatosis, thalassemia, sickle cell disease) similarly reduces bone density. Hyperprolactinemia suppresses GnRH secretion, reducing gonadal steroid production.

• Vitamin D deficiency and impaired calcium absorption: Vitamin D deficiency (serum 25-OH-D <20 ng/mL) impairs intestinal calcium absorption, leading to secondary hyperparathyroidism and enhanced bone resorption. This is particularly common in: (1) northerly latitudes with limited sun exposure; (2) darker-skinned individuals in high-latitude regions; (3) patients with malabsorption disorders; (4) those with limited dietary vitamin D intake; and (5) institutionalized or homebound individuals. Vitamin D insufficiency (20-29 ng/mL) may also contribute to osteoporosis risk, though the optimal threshold remains debated. The relationship between vitamin D status and fracture risk is U-shaped, with both deficiency and excess potentially increasing risk.

• Chronic kidney disease and renal osteodystrophy: Reduced GFR leads to phosphate retention, impaired 1,25-dihydroxyvitamin D production, and secondary (and sometimes tertiary) hyperparathyroidism. The resulting renal osteodystrophy can manifest as high-turnover bone disease (secondary hyperparathyroidism) or low-turnover bone disease (adynamic bone disease). Both patterns increase fracture risk, though through different mechanisms. Patients on chronic dialysis are at particularly high risk.

• Gastrointestinal malabsorption: Conditions causing chronic malabsorption (celiac disease, inflammatory bowel disease, post-gastrectomy, pancreatic insufficiency, biliary disease) impair absorption of calcium, vitamin D, and other nutrients critical for bone health. In celiac disease, both vitamin D malabsorption and chronic inflammation contribute to osteoporosis. Inflammatory bowel disease additionally features systemic inflammation driving osteoclast activation and glucocorticoid use for disease control.

• Rheumatologic diseases: Rheumatoid arthritis causes osteoporosis through multiple mechanisms: (1) chronic inflammatory cytokines (TNF-α, IL-6, IL-17) drive osteoclast activation; (2) disease activity correlates with bone loss; and (3) glucocorticoid therapy for disease control further impairs bone formation. Systemic lupus erythematosus similarly features inflammatory bone loss, compounded by frequent glucocorticoid and immunosuppressive use. Ankylosing spondylitis paradoxically features increased BMD in involved vertebrae (due to osteoproliferation) but unexpectedly high fracture risk due to spinal brittleness and altered bone quality.

• Chronic liver disease and cirrhosis: Hepatic cirrhosis causes osteoporosis through multiple mechanisms: (1) impaired production of proteins essential for bone matrix (Type I collagen, osteocalcin); (2) altered vitamin D metabolism; (3) malabsorption of fat-soluble vitamins; (4) chronic portal hypertension-associated hypogonadism; and (5) increased osteoclast activation from portal endotoxemia. Cholestasis particularly impairs vitamin D and vitamin K absorption.

• Chronic obstructive pulmonary disease: COPD patients have increased osteoporosis risk from multiple factors: (1) systemic inflammation; (2) glucocorticoid use (both systemic and inhaled); (3) reduced physical activity and weight-bearing exercise; (4) nutritional deficiencies; and (5) possibly direct effects of tobacco on bone metabolism. The relationship between airflow obstruction severity and bone loss is imperfect, suggesting multiple independent mechanisms.

• Diabetes mellitus: The relationship between diabetes and bone health is paradoxical. Type 2 diabetes patients often have elevated BMD despite increased fracture risk (Type 2 diabetes bone paradox), while Type 1 diabetes patients have reduced BMD. Both types have impaired bone quality through: (1) advanced glycation end-product (AGE) accumulation, impairing collagen cross-linking; (2) impaired osteoblast function from chronic hyperglycemia; (3) increased adipose tissue in bone marrow (marrow adiposity) which secretes pro-inflammatory adipokines. Type 2 diabetes additionally features increased obesity, reducing fracture risk through mechanical loading. Diabetic complications (particularly renal disease) further compromise bone health.

• Hematologic malignancies and metastatic bone disease: Multiple myeloma directly destroys bone through production of RANKL and other osteoclastogenic factors by malignant plasma cells. Lymphomas similarly produce RANKL and pro-inflammatory cytokines. Metastatic cancer to bone, particularly breast cancer (osteolytic lesions), myeloma, and lymphoma, causes focal bone destruction. Leukemia and lymphoma additionally suppress normal hematopoiesis and osteoblastogenesis.

• Chronic alcohol abuse: Alcohol directly suppresses osteoblast differentiation and function, impairs intestinal calcium absorption, and interferes with vitamin D metabolism. Alcoholic cirrhosis compounds these effects through hepatic dysfunction. Additionally, alcoholism often associates with nutritional deficiency, decreased bone-loading exercise, and increased fracture risk from falls due to neurologic and balance impairment.

• Medication-induced osteoporosis: Beyond glucocorticoids and excess thyroid hormone, several medications impair bone health: (1) aromatase inhibitors for breast cancer suppress estrogen production; (2) androgen deprivation therapy for prostate cancer reduces testosterone; (3) anticonvulsants (particularly phenytoin) induce hepatic vitamin D metabolism; (4) calcineurin inhibitors (tacrolimus, cyclosporine) impair osteoblast function; (5) proton pump inhibitors reduce calcium absorption; (6) thiazolidinediones for diabetes impair osteoblast differentiation; and (7) depo-medroxyprogesterone (DMPA) injections may reduce estrogen production through hypothalamic effects.

• Immobilization and reduced weight-bearing activity: Bone responds to mechanical loading through osteocytes and osteoblasts detecting strain. Prolonged immobilization (from spinal cord injury, stroke, prolonged bed rest) leads to rapid bone loss in weight-bearing bones. Similarly, sedentary lifestyle with minimal weight-bearing exercise fails to provide the mechanical stimulus needed for bone maintenance.

• Genetic factors and family history:

Classic presenting fractures

• Vertebral compression fracture: the most common osteoporotic fracture and the most commonly asymptomatic one (roughly two-thirds are found incidentally on imaging). Trabecular bone predominates in vertebral bodies and is lost earliest, so the anterior cortex buckles under axial load, producing anterior wedging. Symptomatic cases present with acute, focal, midline thoracolumbar pain worsened by standing and relieved by lying flat, without radicular or myelopathic signs.
• Hip (femoral neck or intertrochanteric) fracture: after a fall, the patient presents with groin/hip pain, inability to bear weight, and a shortened, externally rotated limb. Carries the highest morbidity and mortality of any osteoporotic fracture.
• **Distal radius (Colles) fracture**: a fall on an outstretched hand in a postmenopausal woman producing dinner-fork deformity; often the earliest fragility fracture and a sentinel event predicting future hip fracture.
• Proximal humerus, pelvis, and rib fractures round out the "major osteoporotic fracture" group.

Physical findings and their mechanism

• Progressive height loss (>1.5 in / 4 cm from peak height) and **thoracic kyphosis (dowager's hump)**: cumulative anterior vertebral wedging shortens the anterior spinal column.
• Reduced rib–pelvis distance and protuberant abdomen: axial shortening crowds the abdominal viscera, causing early satiety, reflux, and restrictive ventilatory impairment.
• Chronic paraspinal muscle pain from altered biomechanics, not from bone pain itself.

Step 1 — Case finding and screening

• USPSTF: screen all women ≥65 years with bone measurement testing, and screen postmenopausal women <65 whose fracture risk on a formal risk-assessment tool equals that of a 65-year-old white woman. The USPSTF has issued an I statement (insufficient evidence) for screening men; BHOF and the Endocrine Society nonetheless advise testing men ≥70 and any adult ≥50 after a fragility fracture or with a strong secondary risk factor.

Step 2 — Confirmatory test: DXA (dual-energy X-ray absorptiometry) of the lumbar spine and proximal femur.

• T-score compares BMD to a young adult reference: ≥ −1.0 normal; −1.1 to −2.4 osteopenia (low bone mass); ≤ −2.5 = osteoporosis; ≤ −2.5 with a fragility fracture = severe/established osteoporosis. These are the WHO diagnostic criteria.
• Z-score (age/sex-matched) is the correct metric in premenopausal women, men <50, and children; ≤ −2.0 is "below the expected range for age" and mandates a secondary-cause workup.
• Diagnosis can be made clinically without DXA: a hip or vertebral fragility fracture in an adult ≥50 is osteoporosis regardless of T-score.
• Degenerative spondylosis, aortic calcification, vertebral fracture, and prior instrumentation falsely raise the lumbar T-score — use the hip when spine and hip disagree.

Universal measures (all patients)

• Calcium and vitamin D: BHOF advises roughly 1,000–1,200 mg/day elemental calcium (diet preferred) and about 800 IU/day vitamin D in adults ≥50. Correct documented deficiency before starting any antiresorptive to avoid precipitating hypocalcemia.
• Weight-bearing and resistance exercise, smoking cessation, alcohol moderation, and structured fall-risk reduction (vision correction, home hazard removal, deprescribing sedatives/anticholinergics).

• Oral bisphosphonate, representative agent alendronate, taken fasting with a full glass of water while remaining upright ≥30 minutes.
• IV zoledronic acid annually when oral dosing is not tolerated or absorbed.

Escalation / second-line

• RANKL monoclonal antibody: denosumab, subcutaneous every 6 months — preferred in CKD where bisphosphonates are contraindicated.
• Anabolic agents for very high risk (recent fracture, multiple vertebral fractures, T-score markedly low): PTH/PTHrP analogs (teriparatide, abaloparatide) or the anti-sclerostin antibody romosozumab. The Endocrine Society and AACE stress sequence matters: give the anabolic agent first, then consolidate with an antiresorptive; gains are lost if an anabolic follows nothing.
• SERM raloxifene (spine-specific benefit, also lowers invasive breast cancer risk) or menopausal hormone therapy for younger symptomatic postmenopausal women. Calcitonin is last-line.
• Glucocorticoid-induced osteoporosis: the ACR recommends starting an oral bisphosphonate in adults at moderate-to-high fracture risk expected to remain on glucocorticoids.

Complications of the disease

• Hip fracture: the dominant driver of osteoporosis mortality; excess death in the first year is substantial, mediated by VTE, pneumonia, delirium, pressure ulcers, and deconditioning. A displaced femoral neck fracture is a surgical emergency — delayed fixation raises mortality, and disruption of the medial femoral circumflex supply causes avascular necrosis of the femoral head.
• Vertebral compression fractures: progressive kyphosis compresses the thoracic cavity → restrictive ventilatory defect, and crowds the abdomen → early satiety, weight loss, and reflux. Each vertebral fracture sharply raises the risk of the next (fracture cascade).
• Fat embolism syndrome after long-bone fracture: hypoxemia, confusion, and a petechial rash 24–72 hours post-injury — an emergency.
• Neurologic compromise is rare in benign osteoporotic fractures; cord compression, a posterior vertebral body wall lesion, or pedicle destruction should prompt evaluation for malignancy or myeloma, not osteoporosis.
• Loss of independence, fear of falling, and depression — functional outcomes examiners increasingly test.

Complications of therapy

• Pill esophagitis/erosive esophagitis with oral bisphosphonates: retrosternal pain and odynophagia when dosing instructions are violated.
• Acute-phase reaction after first IV zoledronic acid: flu-like myalgia and fever from γδ T-cell activation; self-limited, treat with acetaminophen.
• Hypocalcemia: greatest with denosumab and IV bisphosphonates in vitamin D deficiency or CKD; perioral paresthesias, Chvostek/Trousseau signs, prolonged QT — an emergency if symptomatic.
• Osteonecrosis of the jaw: exposed necrotic mandibular/maxillary bone after dental extraction; rare at osteoporosis doses, far commoner at oncologic dosing.
• Atypical femoral fracture: transverse subtrochanteric or diaphyseal fracture from oversuppressed remodeling, heralded by prodromal thigh or groin pain — image both femurs and stop the drug.
• Denosumab rebound: missed or discontinued doses trigger a surge in bone turnover and multiple vertebral fractures.
• Raloxifene: VTE and fatal stroke risk plus hot flashes. Romosozumab: MI and stroke signal.

• T-score ≤ −2.5 by DXA defines osteoporosis; −1.1 to −2.4 is osteopenia. Use the Z-score, not the T-score, in premenopausal women, men <50, and children — a Z-score ≤ −2.0 demands a hunt for secondary causes.
• A hip or vertebral fragility fracture diagnoses osteoporosis regardless of the DXA number. The single best next step after a fragility fracture in an older adult is to start pharmacotherapy, not to repeat imaging.
• Labs are normal in primary osteoporosis. The classic distractor set: osteomalacia (low/low-normal calcium and phosphate, high ALP, high PTH, low 25-OH vitamin D, Looser zones), Paget disease (isolated markedly elevated ALP with normal calcium), primary hyperparathyroidism (high calcium with inappropriately high PTH), and myeloma (anemia, renal failure, punched-out lytic lesions, M spike).
• FRAX treatment thresholds in the US (BHOF): 10-year risk ≥3% for hip or ≥20% for major osteoporotic fracture in a patient with osteopenia.
• Sequence matters: give an anabolic agent first (teriparatide, abaloparatide, romosozumab) in very-high-risk patients, then follow with a bisphosphonate or denosumab to lock in the gain. Anabolic-after-antiresorptive blunts the response.
• Never simply stop denosumab — rebound osteoclast activation causes multiple vertebral fractures. Always bridge to a bisphosphonate. By contrast, a bisphosphonate drug holiday is reasonable after about 5 years of oral or 3 years of IV therapy in patients no longer at high risk, because bisphosphonates persist in the skeleton.
• New thigh or groin pain in a patient on long-term bisphosphonate = atypical femoral fracture until proven otherwise; image both femurs.
• Steroids are the classic secondary cause: ACR advises bisphosphonate prophylaxis in moderate-to-high-risk adults starting long-term glucocorticoids. Bone loss is fastest in the first 6–12 months — do not wait for a follow-up DXA.
• Screening buzzword: USPSTF — all women ≥65; men carry an I statement.